BusinessAdamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017By Nasdaq OMXFeb 22, 2018, 9:01 PM UTC
BusinessAdamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical PracticeBy Nasdaq OMXFeb 8, 2018, 2:01 PM UTC
BusinessAdamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease PatientsBy Nasdaq OMXJan 8, 2018, 9:41 PM UTC
BusinessAdamas Reports Recent Achievements and Third Quarter 2017 Financial ResultsBy Nasdaq OMXNov 2, 2017, 8:02 PM UTC
BusinessFDA Recognizes Orphan Drug Exclusivity for Adamas’ GOCOVRI™By Nasdaq OMXOct 25, 2017, 4:31 PM UTC
